Meta-Analysis of Tyrosine Kinase Inhibitor Combination Therapy for Glioblastoma

A 2026 meta-analysis synthesizing evidence from 10 randomized controlled trials published up to January 10, 2026, encompassing 1,435 glioblastoma patients. The study, authored by Pan Wei, evaluates the efficacy and safety of tyrosine kinase inhibitor combination therapies, reporting pooled hazard ratios and risk ratios for outcomes like progression-free survival and adverse events.

Use Cases

• Assessing treatment efficacy signals for progression-free survival and objective response rate based on pooled hazard and risk ratios.
• Evaluating safety profiles of combination therapies based on reported incidences of specific adverse events like neutropenia and diarrhea.
• Conducting subgroup analyses on treatment regimens or patient status using the stratified results mentioned in the description.
• Applying trial sequential analysis methods to control for false conclusions in meta-analyses as described in the methodology.

Strengths

• Includes 10 randomized controlled trials, a standard for high-quality evidence synthesis.
• Reports specific statistical results, including hazard ratios with 95% confidence and prediction intervals.
• Employs a systematic literature search across multiple major databases (PubMed, Cochrane, Web of Science, Embase).
• Registered as a systematic review with a PROSPERO identifier (CRD420261293988).

Limitations

• The dataset is a single 18.2 KB DOCX document, which severely limits the scope and granularity of the underlying data.
• Column-level documentation is absent; field semantics and raw trial data must be inferred from the report text.
• The analysis includes trials only up to January 2026; its conclusions may be superseded by newer research.

Provenance

Source

figshare

Collection Method

Systematic literature review and meta-analysis of identified randomized controlled trials.

Time Range

Trials published up to January 10, 2026.

Freshness

Last updated 2026-04-20 04:11:46.

Geography

null